Prosecution Insights
Last updated: November 04, 2026
Application No. 18/251,803

A HIGH-THROUGHPUT AUTOMATED GENE SYNTHESIS DEVICE BASED ON CLUSTER ARRAY

Non-Final OA §102§103§112
Filed
May 04, 2023
Priority
Mar 29, 2021 — CN 202110344493.0 +1 more
Examiner
HOBBS, MICHAEL L
Art Unit
1799
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Dynege Bioscience Corporation
OA Round
1 (Non-Final)
69%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allowance Rate
818 granted / 1189 resolved
+3.8% vs TC avg
Strong +28% interview lift
Without
With
+28.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
26 currently pending
Career history
1212
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
43.1%
+3.1% vs TC avg
§102
22.8%
-17.2% vs TC avg
§112
20.4%
-19.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1189 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of Group II, claims 25-29 in the reply filed on 02/24/2026 is acknowledged. The traversal is on the ground(s) that the claimed invention employs a cluster array, the microwell has a chemical modification on the inner walls or filled with a solid phase and that the clusters correspond to the wells of a microwell plate. This is not found persuasive because Applicant’s point 1 on page 7 is not found persuasive since Banyai teaches an array of micropore/microwell clusters (Fig. 4; [0207]; [0208]). Moreover, these clusters are placed adjacent to a microwell ([0609]) and form an array of microwells. Regarding Applicant’s point 2, Banyai discloses functionalizing the surface of the microstructure/micropore ([0207; Fig. 4) where this functionalized surface is on the inner walls of the pore. For point 3, each cluster of Banyai corresponds to a microwell ([0208]). Applicant argues on the bottom of page 7 to the end of the first full paragraph on page 8 that Banyai does not teach or suggest using the clusters with a standard SBS-format plate. First, this requirement is not a common technical feature of the claimed invention and is a feature relied upon, but not currently claimed in claims 15 or 25. Second, even if the plates of Banyai are not a SBS-format plate, this would be an obvious modification to one of ordinary skill in the art as standard microtiter plate formats are conventional and well-known within the biological arts and would be obvious to the skilled artisan. Applicant’s statement in the second full paragraph on page 8 regarding the allegedly innovative nature of the claimed plate is not found persuasive as the applied reference of Banyai discloses the special technical feature of the claimed inventions and the format of the plate is not currently claimed. Therefore, the inventions of Groups I and II lack unity and a restriction between the two inventions is proper. The requirement is still deemed proper and is therefore made FINAL. Claims 15-24 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 02/24/2026. Sequence Listing This application complies with the sequence rules and the sequences have been entered by the Scientific and Technical Information Center. Claim Interpretation It should be noted whenever the term “or” is used between claim limitations that this will be interpreted as the prior art only needs to meet one or the other limitation in order to meet the claim. Also, any other limitation within the claim drawn to one of the “or” limitations will be interpreted as optional and not required for the prior art to either anticipate or ender the claim obvious. Finally, if the term “and/or” appears in the claim, this will be treated as “or” for purposes of claim interpretation and the application of the prior art. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 25, 27 and 30-38 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 25 recites the limitation "the micropore" in line 4. There is insufficient antecedent basis for this limitation in the claim. Claim 25 recites the limitation "the solid phase carriers" in line 6. There is insufficient antecedent basis for this limitation in the claim. Claim 25 recites the limitation "the gene synthesis device" in line 8. There is insufficient antecedent basis for this limitation in the claim. It is recommended to amend this to the high-throughput gene synthesis device. Claims 27 and 30-38 are rejected under 35 U.S.C. 112b since the claims depend upon and incorporate all the limitations of claim 25. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 25, 27, 30-33, 35 and 37 are rejected under 35 U.S.C. 102a1 as being anticipated by Banyai et al. (US 2015/0038373 A1 – hereafter ‘373). ‘373 (Banyai) discloses a system for the synthesizing of large gene libraries ([0004]) that includes the following limitations for claim 25: “A method for oligonucleotide synthesis”: ‘373 discloses a method for synthesizing oligonucleotides ([0011]). “the method for oligonucleotide synthesis comprises the steps of”: The method of ‘373 includes the following steps. “adding phosphonamidite monomers or auxiliary reagents to the micropores of a high-throughput gene synthesis device utilizing a liquid dispensing device”: ‘373 discloses the step of applying reagents to the micropores as a drop ([0029]) by a liquid dispensing device such as an inkjet pump. “conducting a reaction on the solid phase carriers within the micropores to synthesize the oligonucleotides”: ‘373 discloses synthesizing the oligonucleotides, i.e. conducting a reaction, on the functionalized surface of the pores ([0140]; [0027]; [0029]) where this functionalized surface is being interpreted as the solid phase carrier of the instant application. “matching the gene synthesis device with the microwell plate”: The microwells of ‘373 are adjacent to the micropores and therefore the gene synthesis device is matched with the plate ([0609]). “recovering the oligonucleotides synthesized in each cluster of the micropores into a single well within the microwell plate”: ‘373 discloses the step of recovering the oligonucleotides from the micropores within each well ([0423]; [0642]). “the gene synthesis device includes a substrate and a microwell plate”: ‘373 discloses that the device includes a lower substrate layer and a layer of microwells (Fig. 4; [0207]) where this combination is being interpreted as the device of the instant application. “the substrate is provided with a plurality of clusters of micropores”: ‘373 discloses that the micropores are in clusters ([0208]) that are used for the reaction. “an inner wall surface of each of the micropores is chemically modified as a solid phase carrier for nucleic acid synthesis, or each of the micropore is filled with a solid phase carrier for nucleic acid synthesis”: ‘373 discloses the step of coating the inner surface with a functionalized surface ([0028]; [0029]; [0030]) where this surface is being interpreted as the chemically modified surface that is being used as a solid phase carrier. “the plurality of clusters of the micropores are arranged in a cluster array wherein each cluster of the micropores having the same size and position as a corresponding well on the microplate.”: The clusters are arranged as an array (Fig. 25C; [0018]; [0020]) where the clusters have a size and position that correspond to a well (Fig. 4). For claim 27, the volume of the inkjet pump is a micro-nano liter dispensing head ([0202]; [0063]). For claim 30, the micropore of ‘373 is being interpreted as a cylindrical micropore. For claim 31, ‘373 discloses that the substrate can be made of silicon ([0017]) and is therefore being interpreted as a silicon wafer. For claim 32, ‘373 discloses using processes that are being interpreted as a MEMS micro-nano processing method such as nanoelectromechanical techniques ([0215]). For claim 33, ‘373 discloses using plastics for the substrate ([0326]) where this is being interpreted as a plastic plate. For claim 35, ‘373 discloses using beads, i.e. microspheres ([0477]) as the solid support and discloses that the solid support can be glass ([0028]). For claim 37, ‘373 discloses that there can be anywhere from 1 to 50 loci or micropores in the cluster ([0208]). Therefore, ‘373 meets the limitations of claims 25, 27, 30-33, 35 and 37. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 38 is rejected under 35 U.S.C. 103 as being unpatentable over Banyai et al. (US 2015/0038373 A1 – hereafter ‘373) in view of Van Beuningen et al. (US 2006/0286555 A1 – hereafter ‘555). For claim 38, ‘373 (Banyai) does not explicitly disclose that the microwell is a standard SBS plate, however, standard SBS plates are well-known and conventional in the prior art and would have been obvious to one of ordinary skill in the art at the time of the earliest effective filing date barring evidence to the contrary. ‘555 (Van Beuningen) discloses an apparatus that uses a microtiter plate biochemical reactions(Abstract) that for claim 38 uses a standard SBS microplate for the assays ([0039]). This makes the plate compatible with standard liquid handling equipment ([0044]). Therefore, it would have been obvious to one of ordinary skill in the art at the earliest effective filing date to employ the standard plate of ‘555 within ‘373 in order to perform the assay or oligonucleotide synthesis. The suggestion for doing so at the time would have been in order to allow a parallel synthesis of a large number of polymers, resulting in a very cost-efficient price per polymer ([0044]). Claim 34 is rejected under 35 U.S.C. 103 as being unpatentable over Banyai et al. (US 2015/0038373 A1 – hereafter ‘373) in view of Duffy et al. (US 2003/0032046 A1 – hereafter ‘046). ‘373 differs from the instant claim regarding either 3D printing or injection molding the pores. It should be noted that these processes are conventional and well-known within the biological arts and would have been obvious to one of ordinary skill in the art to employ in the manufacturing of the gene synthesis device. ‘046 (Duffy) discloses a method for performing biochemical assays (Abstract) that for claim 34 includes forming wells with injection molding ([0098]). Therefore, it would have been obvious to one of ordinary skill in the art at the earliest filing date to employ the conventional step of forming the device with injection molding as taught by ‘046 within ‘373 in order to have a cost effective means of manufacturing the gene synthesis device. The suggestion for doing so at the time would have been in order to use suitable techniques to manufacture the wells ([0098]). Allowable Subject Matter Claim 36 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: For claim 36, the prior art fails to teach or fairly suggest where the solid phase carriers are immobilized by mixing the solid phase carriers with high-density polyethylene spheres and sintering the spheres. The closest prior art is Banyai et al. (2015/0038373 A1) which discloses a multiwell plate with clusters of micropores in order to synthesize oligonucleotides, but Banyai does not teach or fairly suggest the step where the solid phase carriers are immobilized by mixing the solid phase carriers with high-density polyethylene spheres and sintering the spheres. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. MacBeath et al. (US 2003/0026739 A1) discloses an interface between microarrays and microtiter plates. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL L HOBBS whose telephone number is (571)270-3724. The examiner can normally be reached Variable, but generally 8AM-5PM M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Marcheschi can be reached at 571-272-1374. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL L HOBBS/Primary Examiner, Art Unit 1799
Read full office action

Prosecution Timeline

May 04, 2023
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781169
SYSTEMS AND METHODS FOR PARTICLE SEPARATION AND CONCENTRATION
3y 3m to grant Granted Nov 03, 2026
Patent 12779475
CELL SEPARATION CONTROL DEVICE
2y 8m to grant Granted Nov 03, 2026
Patent 12781170
REACTOR PLANT AND METHOD TO CONTROL PERFORMANCE
2y 11m to grant Granted Nov 03, 2026
Patent 12774437
ROBOTIC BARCODE TAGGING OF DISTINCT CELL POPULATIONS IN INTACT TISSUE
4y 1m to grant Granted Oct 27, 2026
Patent 12767943
SPECIMEN PROCESSING APPARATUS
2y 11m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
69%
Grant Probability
97%
With Interview (+28.2%)
3y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1189 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month